Medical devices, IVDs, cosmetics and compliance technology.Explore SMEDTEC OS
← Back to Insights

FDA's 2026 Inspection Overhaul: What QMSR Means for Your QMS

Sherif Elkhadem
16 March 2026
6 min read
FDA's 2026 Inspection Overhaul: What QMSR Means for Your QMS

On February 2, 2026, the FDA quietly ended an era. After more than two decades, the Quality System Inspection Technique (QSIT) — the structured inspection framework that regulatory affairs and quality teams have built their audit preparation around — was officially retired. In its place: a modernized, risk-based inspection process under the Quality Management System Regulation (QMSR) and an updated Compliance Program Manual (CP 7382.850). This isn't just procedural housekeeping. It represents a fundamental shift in how the FDA evaluates medical device manufacturers, and if your quality systems are still optimized for QSIT-era inspections, you're already behind the curve.

What Actually Changed: From QSIT to Risk-Based QMSR Inspections

QSIT provided a predictable, subsystem-by-subsystem approach to inspections. Investigators followed a defined pathway through the seven quality system subsections, examining management controls, design controls, CAPA, and so forth in a relatively standardized sequence. It was prescriptive, yes, but it was also known territory. Quality managers could anticipate inspection flows, prepare documentation accordingly, and train teams on what to expect when FDA investigators walked through the door.

The new risk-based inspection model under QMSR changes that calculus entirely. Rather than following a one-size-fits-all subsystem checklist, FDA investigators now have the authority and expectation to tailor their inspections based on the specific risk profile of your device, your manufacturing processes, your post-market surveillance data, and your compliance history. The Compliance Program Manual now emphasizes a holistic, systems-thinking approach that evaluates how effectively your QMS actually manages risk — not just whether you have the right procedures documented.

This shift mirrors the broader harmonization agenda with ISO 13485:2016 and aligns with the FDA's strategic pivot toward risk-based resource allocation across its entire regulatory portfolio. It also dovetails with two other significant FDA developments: the launch of the Adverse Event Monitoring System (AEMS) and new guidance on medical devices with weight loss indications. Both initiatives underscore the agency's focus on leveraging real-world data, transparency, and targeted oversight rather than blanket regulatory protocols.

The AEMS Connection: Post-Market Data Now Drives Pre-Inspection Risk Profiling

The timing of the AEMS launch is not coincidental. FDA's new Adverse Event Monitoring System provides unprecedented public transparency into device safety signals, but it also serves as a critical data source for the agency's internal risk-based inspection planning. Under the updated CP manual, FDA investigators can now access consolidated adverse event data, recall histories, and post-market performance trends before they ever step foot in your facility. This pre-inspection intelligence allows them to identify specific areas of concern — a problematic component supplier, a pattern of customer complaints related to a design element, or a trend in field corrective actions — and structure their inspection accordingly.

For manufacturers, this creates a new imperative: your post-market surveillance and complaint handling systems are no longer just compliance checkboxes. They are the earliest indicators of where FDA scrutiny will focus during your next inspection. If your CAPA system shows recurring issues that haven't been adequately resolved, or if your MDR submissions reveal patterns you haven't proactively addressed through design changes or process improvements, expect those areas to become focal points under the new risk-based inspection regime. The days of treating post-market activities as separate from inspection readiness are over.

What This Means for Your Team: Practical Implications for RA and QA

First, audit your audit preparation. If your inspection readiness protocols are still organized around QSIT subsections, you need to reorient them around risk. That means understanding your own device's risk profile from the FDA's perspective: What are the critical to quality attributes? Where are your highest-risk suppliers and processes? What post-market signals have emerged in the past 24 months? Your internal mock audits should simulate a risk-targeted approach, not a subsystem walkthrough.

Second, integrate your post-market data streams into your QMS in a way that supports proactive risk management, not just reactive compliance. If an FDA investigator can pull AEMS data showing an uptick in complaints related to your device, you should already have that data, already have analyzed it, and already have documented your risk evaluation and any mitigating actions. The quality of your trend analysis, the timeliness of your CAPA responses, and the robustness of your effectiveness checks will all be scrutinized more intensively under the new model.

Third, train your teams differently. It's no longer sufficient to train employees on procedure compliance alone. They need to understand the risk rationale behind those procedures, how their activities connect to broader quality and safety outcomes, and how to articulate that understanding during investigator interviews. FDA's systems-thinking approach means investigators will probe whether your organization truly has a risk-based quality culture or merely risk-based documentation.

Fourth, pay special attention if you're working in emerging device categories like digital therapeutics, AI-enabled diagnostics, or — as highlighted by the recent FDA guidance — weight loss devices. These areas are under heightened regulatory scrutiny, and the risk-based inspection model means you're more likely to face targeted, in-depth inspections focused on novel risk areas like software validation, algorithm transparency, or clinical claims substantiation. The new weight loss device guidance, for example, establishes specific premarket expectations around clinical evidence and labeling that will undoubtedly inform post-market inspection priorities.

Looking Ahead: The Inspection Landscape in 2026 and Beyond

The shift to risk-based inspections also has broader strategic implications for how you manage your regulatory roadmap. Manufacturers with strong post-market performance, robust complaint handling, and effective CAPA systems may see less frequent or less intensive inspections over time, as FDA allocates its inspection resources toward higher-risk firms and products. Conversely, companies with compliance red flags, recurring quality issues, or devices in high-scrutiny categories should expect more frequent and more focused oversight.

This creates an incentive structure that rewards proactive quality management and transparency. If you're voluntarily conducting post-market studies, publishing real-world evidence, engaging with FDA through pre-submission meetings, and demonstrating continuous improvement in your QMS, you're building a risk profile that works in your favor. If you're doing the regulatory minimum and treating inspections as adversarial events to be managed, the new model will expose those gaps more quickly and more consequentially.

For UK-based manufacturers navigating both MHRA and FDA requirements, this also highlights the continued divergence in inspection philosophies post-Brexit, even as both regulators claim alignment with ISO 13485. The FDA's move toward risk-based inspections is more formalized and data-driven than what we've seen from MHRA to date, though the principles of risk-based oversight are certainly present in both frameworks. Manufacturers serving both markets need dual-track inspection strategies that account for these nuances.

Key Takeaways

  • FDA's QSIT framework is gone. The new risk-based inspection model under QMSR and CP 7382.850 tailors inspections to your device's risk profile, compliance history, and post-market performance data.
  • Post-market surveillance is now pre-inspection intelligence. The AEMS launch gives FDA — and the public — unprecedented access to adverse event data that will inform where investigators focus during your next audit.
  • Inspection readiness must shift from subsystem checklists to risk-based scenarios. Mock audits, training, and documentation strategies should reflect the critical-to-quality attributes and risk areas specific to your device.
  • Proactive quality management will be rewarded. Manufacturers with strong post-market systems and transparent risk management may see reduced inspection intensity, while those with recurring issues will face more targeted scrutiny.

The retirement of QSIT marks more than a procedural update — it signals the FDA's commitment to a more sophisticated, data-driven approach to quality oversight. For manufacturers, this is both challenge and opportunity. Those who adapt their quality systems to genuinely manage risk, rather than simply document compliance, will find themselves better prepared not just for inspections, but for the entire product lifecycle. At SMEDTEC, we're helping clients across the UK and beyond navigate this transition, from QMS gap assessments to mock audit preparation tailored to the new risk-based paradigm. The inspection landscape has shifted. Make sure your quality systems shift with it.

Sources cited in this digest

  • MedTech Intelligence

Need Regulatory Guidance?

Get expert help with your medical device regulatory strategy. From EU MDR compliance to FDA submissions, we're here to help.

Get Started →More Articles